Figures computed from official regulatory filings — .
Ownershipinsiders 0% · institutions 0%
In USD · as of Oct 26, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Pharmagen, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Pharmagen, Inc. distributes specialty drugs to hospitals, acute care facilities, surgery centers, and other healthcare practitioners in the United States. The company sources and distributes specialty drugs, blood plasma derivatives, specialty products, vaccines, anti-infectives, and hard-to-find pharmaceuticals. It offers plasma derivatives for treating serious medical conditions, such as cancer, hemophilia, rheumatoid arthritis, multiple scleroses, blood disorders, hepatitis, and HIV; and specialty products for treating respiratory, oncology, cardiovascular, and hormonal syndromes. The company also manufactures and distributes health supplements, including Clotamin, a specialized over-the-counter multivitamin dietary supplement for patients on Warfarin. In addition, it sells traditional pharmaceuticals to its distribution customers, such as antibiotics, vaccines, and other oral and injectable pharmaceuticals; and specializes in the formulation of drugs. The company was formerly known as Sunpeaks Ventures, Inc. and changed its name to Pharmagen, Inc. in January 2013. Pharmagen, Inc. is based in Silver Spring, Maryland.
Market information source · Oct 26, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 26, 2026
Open-market timeline · full history
4 buys3 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Perry Stephen M. | Other | n/a (No price was disclosed in the filing) | SEC | ||
| Perry Stephen M. |
| Other |
| n/a (No price was disclosed in the filing) |
| SEC |
| Wolpow Richard | BuyD (derivative) | $100K | First in 12mo | SEC |
| BARCH MACKIE | Buy | n/a (No price was disclosed in the filing) | conv 87Cluster | SEC |
| BARCH MACKIE | SellD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| BARCH MACKIE | BuyD (derivative) | n/a (No price was disclosed in the filing) | Cluster | SEC |
| BARCH MACKIE | Sell | n/a (No price was disclosed in the filing) | SEC |
| BARCH MACKIE | Sell | n/a (No price was disclosed in the filing) | SEC |
| BARCH MACKIE | Sell | n/a (No price was disclosed in the filing) | SEC |
| BETHESDA HOLDINGS LLC | BuyD (derivative) | n/a (No price was disclosed in the filing) | ClusterFirst in 12mo | SEC |
| OLD LINE PARTNERS LLC | Buy | n/a (No price was disclosed in the filing) | conv 69ClusterFirst in 12mo | SEC |
| BETHESDA HOLDINGS LLC | Buy | n/a (No price was disclosed in the filing) | conv 69ClusterFirst in 12mo | SEC |
| OLD LINE PARTNERS LLC | BuyD (derivative) | n/a (No price was disclosed in the filing) | ClusterFirst in 12mo | SEC |
| BARCH MACKIE | BuyD (derivative) | n/a (No price was disclosed in the filing) | First in 12mo | SEC |
| BARCH MACKIE | Buy | n/a (No price was disclosed in the filing) | conv 74First in 12mo | SEC |